93 Himachal-Made Drug Samples Fail Quality Tests, Recall Planned

Himachal Pradesh’s pharmaceutical sector has come under renewed scrutiny after 93 medicine samples manufactured in the state failed prescribed quality tests, among 330 samples found substandard across India.

According to a drug alert issued by the state laboratory and the Central Drugs Standard Control Organisation (CDSCO), the failed samples were linked to pharmaceutical units operating across some of Himachal’s major drug-manufacturing hubs.

Of the Himachal cases, products from 73 pharmaceutical companies in Solan district, 18 in Sirmaur and two in Una were found not to meet the required quality standards. The findings have put the spotlight on industrial areas such as Baddi, Barotiwala, Nalagarh and Kala Amb, which are home to a large number of pharmaceutical units.

The medicines that failed the tests cover a wide range of commonly used treatments, including drugs for fever, acidity, pain, cough, anaemia, allergies, infections, high blood pressure, inflammation, malaria and thyroid disorders.

Drug authorities are expected to initiate action against the companies concerned under the Drugs and Cosmetics Act. Independent testing of the affected medicines is also planned, while stocks from the batches that failed the tests will be recalled from the market.

The latest findings have once again brought drug quality into focus in Himachal Pradesh, one of the country’s major pharmaceutical manufacturing centres.

With several manufacturers from the state’s key industrial belts figuring in the list, the focus will now be on regulatory action, independent testing and the recall of affected batches.

Editing note: I removed the copied HTML formatting and the previous “What I changed” section, tightened repetitive passages, and kept the article in a clean, natural, publication-ready news style.